The World Health Organization’s Stop TB Department has published the fourth edition of Treatment of Tuberculosis: Guidelines. The guidelines contain a number of new recommendations, including a call to discontinue regimens based on just two months of rifampicin (2HRZE/6HE). They reinforce prior WHO recommendations for drug susceptibility testing (DST) at the start of therapy for all previously treated patients, and provide guidance for appropriate treatment approaches in the light of advances in laboratory technology and the country’s progress in building laboratory capacity. They also reaffirm recommendations for supervised treatment, as well as the use of fixed-dose combinations of anti-TB drugs and patient kits as further measures for preventing the acquisition of drug resistance.

You can read the report here: http://www.who.int/tb/publications/tb_treatmentguidelines/en/index.html